Advertisement

Tumor Biology

, Volume 37, Issue 5, pp 6343–6348 | Cite as

Genetic variants in IL12 influence both hepatitis B virus clearance and HBV-related hepatocellular carcinoma development in a Chinese male population

  • Aihua Tan
  • Yong Gao
  • Ziting Yao
  • Shining Su
  • Yonghua Jiang
  • Yuanliang Xie
  • Xiaoying Xian
  • Zengnan Mo
Original Article

Abstract

IL12 plays a major role not only in inducing appropriate immune responses against viral infections (including HBV) but also in the antitumor immune response. This study was conducted to investigate the relationships of genetic variants in IL12 with hepatitis B virus (HBV) clearance and development of HBV-related hepatocellular carcinoma (HCC). We genotyped three single nucleotide polymorphisms (SNPs) of the IL12A (rs568406 and rs2243115) and IL12B (rs3212227) in 395 HBV-positive HCC patients, 293 persistent HBV carriers and 686 subjects with HBV natural clearance from southern China, using the improved multiplex ligase detection reaction (iMLDR) method. Logistic regression analysis adjusted for age, smoking, and alcohol consumption status showed that rs568408 variant genotypes were significantly associated with host HBV-related HCC risk when compared with persistent HBV carriers, and carriers of the GA + AA genotype decreased the HCC risk in comparison with GG carriers (adjusted OR = 0.53, 95 % CI 0.35–0.80, P = 0.002). No relationships between the rs2243115 and rs3212227 SNPs and HCC risk were observed (all P > 0.05). Besides, rs568408 showed an approaching significant effect on susceptibility to HBV persistent infection (adjusted OR = 1.34, 95 % CI 0.99–1.81, P = 0.057 in dominant genetic models). Furthermore, the TG haplotype was observed to be associated with a significantly increased risk of HBV-related HCC (OR = 1.42, 95 % CI 1.10–1.83, P = 0.006), while TA haplotype was associated with a decreased risk of HBV-related HCC (OR = 0.61, 95 % CI 0.45–0.83, P = 0.002). Our results reveal that the IL12A rs568408 variant may be a marker SNP for risk of both HBV clearance and HBV-related HCC development.

Keywords

IL12 gene Persistent HBV infection HBV-related HCC 

Notes

Acknowledgments

This study was supported by the Guangxi Natural Science Foundation (2012GXNSFBA053117), Guangxi Natural Science Fund for Innovation Research Team (2013GXNSFFA019002), Guangxi Collaborative Innovation Center for genomic and personalized medicine (201319), Guangxi Natural Science Fund for Distinguished Young Scholars (2012jjFA40011), and Program for New Century Excellent Talents in University (NCET-12-0653).

Compliance with ethical standards

Conflicts of interest

None

Supplementary material

13277_2015_4520_MOESM1_ESM.doc (30 kb)
Supplementary Table 1 SNPs and PCR primer for IL12 allele genotyping. (DOC 30 kb)
13277_2015_4520_MOESM2_ESM.docx (13 kb)
Supplementary Table 2 Linkage disequilibrium (LD) information of IL12A variations (DOCX 13 kb)

References

  1. 1.
    Ferlay J, S. I., Ervik M, Dikshit R, Eser S, Mathers & C, e. a. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC cancer base no. 11 [Internet]. . Lyon, France: International Agency for Research on Cancer 2013.Google Scholar
  2. 2.
    Yeh FS, Y. M., Mo CC, Luo S, Tong MJ, Henderson BE. Hepatitis B virus, aflatoxins, and hepatocellular carcinoma in southern Guangxi, China. Cancer Res; 1989. 2506–2509.Google Scholar
  3. 3.
    Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Taiwan Community-Based Cancer Screening Project Group. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347:168–74.CrossRefPubMedGoogle Scholar
  4. 4.
    lecture., C. F. R.-W. a. Viruses, immunity, and cancer: lessons from hepatitis B. . Am J Pathol; 2000. 1117–1132.Google Scholar
  5. 5.
    Wolf SF, Sieburth D, Sypek J. Interleukin 12: a key modulator of immune function. Stem Cells. 1994;12:154–68.CrossRefPubMedGoogle Scholar
  6. 6.
    Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3:133–46.CrossRefPubMedGoogle Scholar
  7. 7.
    Becskei A, Grusby M. Contribution of IL-12R mediated feedback loop to Th1 cell differentiation. FEBS Lett. 2007;581(27):5199–206.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Yoshimoto T, Takeda K, Tanaka T, Ohkusu K, Kashiwamura S, Okamura H, et al. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J Immunol. 1998;161(7):3400–7.PubMedGoogle Scholar
  9. 9.
    Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med. 1993;178:1223–30.CrossRefPubMedGoogle Scholar
  10. 10.
    Noguchi Y, Culpepper JA, Richards EC, Old LJ. Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. Proc Natl Acad Sci U S A. 1996;93:11798–801.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Nanni P, Nicoletti G, De Giovanni C, Landuzzi L, Di Carlo E, Cavallo F, et al. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med. 2001;194:1195–205.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Nieters A, Yuan J, Sun CL, Zhang ZQ, Stoehlmacher J, Govindarajan S, et al. Effect of cytokine genotypes on the hepatitis B virus-hepatocellular carcinoma association. Cancer Res. 2005;103(4):740–8.Google Scholar
  13. 13.
    Ognjanovic S, Yuan J, Chaptman AK, Fan Y, Yu MC. Genetic polymorphisms in the cytokine genes and risk of hepatocellular carcinoma in low-risk non-Asians of USA. Carcinogenesis. 2009;30(5):758–62.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Liu L, Xu Y, Liu Z, Chen J, Zhang Y, Zhu J, et al. IL12 polymorphisms, HBV infection and risk of hepatocellular carcinoma in a high-risk Chinese population. Int J Cancer. 2011;128(7):1692–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Park JS, Cheong J, Kang JK, Cho JH, Yu S, Shin HD, et al. Association of interleukin-12 gene polymorphism with persistence of hepatitis B virus infection and hepatocellular carcinoma. Korean J Gastroenterol. 2007;50(5):313–8.PubMedGoogle Scholar
  16. 16.
    Tan A, Gao Y, Yang X, Zhang H, Qin X, Mo L, et al. Low serum osteocalcin level is a potential marker for metabolic syndrome: results from a Chinese male population survey. Metabolism. 2011;60:1186–92.CrossRefPubMedGoogle Scholar
  17. 17.
    Hu L, Xiangjun Z, Liu J, Chu M, Pan S, Jiang J, et al. Genetic variants in human leukocyte antigen/DP-DQ influence both hepatitis B virus clearance and hepatocellular carcinoma development. Hepatology. 2012;55(5):1426–31.CrossRefPubMedGoogle Scholar
  18. 18.
    Shi YY, He L. SHesis. A powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005;15(2):97–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Saxena R, Chawla Y, Verma I, Kaur J. Effect of IL-12B, IL-2, TGF-b1, and IL-4 polymorphism and expression on hepatitis B progression. J Interferon Cytokine Res. 2014;34(2):117–28.CrossRefPubMedGoogle Scholar
  20. 20.
    Wang C, Zhang X, Zhu B, Hu D, Wu J, Yu R, et al. Relationships between tumour necrosis factor-α, interleukin-12B and interleukin-10 gene polymorphisms and hepatitis B in Chinese Han haemodialysis patients. Nephrology (Carlton). 2012;17(2):167–74.CrossRefGoogle Scholar
  21. 21.
    Lee KM, Shen M, Chapman RS, Yeager M, Welch R, He X, et al. Polymorphisms in immunoregulatory genes, smoky coal exposure and lung cancer risk in Xuan Wei, China. Carcinogenesis. 2007;28(7):1437–41.CrossRefPubMedGoogle Scholar
  22. 22.
    Chen X, Han S, Wang S, Zhou X, Zhang M, Dong J, et al. Interactions of IL-12A and IL-12B polymorphisms on the risk of cervical cancer in Chinese women. Clin Cancer Res. 2009;15(1):400–5.CrossRefPubMedGoogle Scholar
  23. 23.
    Grohmann U, Belladonna M, Bianchi R, Orabona C, Ayroldi E, Fioretti MC, et al. IL-12 acts directly on DC to promote nuclear localization of NF-kappaB and primes DC for IL-12 production. Immunity. 1998;9(3):315–23.CrossRefPubMedGoogle Scholar
  24. 24.
    Pikarsky E, Porat R, Stein I, Abramovitch R, Amit S, Kasem S, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431(7007):461–6.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Aihua Tan
    • 1
    • 2
  • Yong Gao
    • 2
  • Ziting Yao
    • 2
  • Shining Su
    • 3
  • Yonghua Jiang
    • 2
  • Yuanliang Xie
    • 2
  • Xiaoying Xian
    • 2
  • Zengnan Mo
    • 2
  1. 1.Department of chemotherapyThe Affiliated Tumor Hospital of Guangxi Medical UniversityNanningChina
  2. 2.Center for Genomic and Personalized MedicineGuangxi Medical UniversityNanningChina
  3. 3.TalentCloud Information Technology LtdNanningChina

Personalised recommendations